These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 22417788)
1. Bronchodilator response in patients with normal baseline spirometry. Hegewald MJ; Townsend RG; Abbott JT; Crapo RO Respir Care; 2012 Oct; 57(10):1564-70. PubMed ID: 22417788 [TBL] [Abstract][Full Text] [Related]
2. When should a reversibility test be performed on patients with early stages of asthma and normal spirometry? Sposato B; Mariotta S; Ricci A J Asthma; 2008 Aug; 45(6):479-83. PubMed ID: 18612900 [TBL] [Abstract][Full Text] [Related]
3. Argument for changing criteria for bronchodilator responsiveness. Hansen JE; Sun XG; Adame D; Wasserman K Respir Med; 2008 Dec; 102(12):1777-83. PubMed ID: 18701269 [TBL] [Abstract][Full Text] [Related]
4. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease. Walker PP; Calverley PM COPD; 2008 Jun; 5(3):147-52. PubMed ID: 18568838 [TBL] [Abstract][Full Text] [Related]
5. Comparison of bronchodilator response in patients with asthma and healthy subjects using spirometry and oscillometry. Nair A; Ward J; Lipworth BJ Ann Allergy Asthma Immunol; 2011 Oct; 107(4):317-22. PubMed ID: 21962091 [TBL] [Abstract][Full Text] [Related]
6. The forgotten message from gold: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Ben Saad H; Préfaut C; Tabka Z; Zbidi A; Hayot M Pulm Pharmacol Ther; 2008 Oct; 21(5):767-73. PubMed ID: 18555715 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of interpretation strategies and substantial bronchodilator response in pediatric patients with normal baseline spirometry. Hsu DP; Ocampo TF; DiGiovanni HA; Gil ER Respir Care; 2013 May; 58(5):785-9. PubMed ID: 23625894 [TBL] [Abstract][Full Text] [Related]
8. Post-bronchodilator spirometry reference values in adults and implications for disease management. Johannessen A; Lehmann S; Omenaas ER; Eide GE; Bakke PS; Gulsvik A Am J Respir Crit Care Med; 2006 Jun; 173(12):1316-25. PubMed ID: 16556696 [TBL] [Abstract][Full Text] [Related]
9. [Comparison of lung volume response with airflow response to bronchodilator in patients with chronic obstructive pulmonary disease]. Zhang FQ; Zheng JP; Wang JH; Lu WB; Wu RX; Li XS; Xian QZ; Gao Y; Jiang M Zhonghua Jie He He Hu Xi Za Zhi; 2010 Feb; 33(2):109-13. PubMed ID: 20367950 [TBL] [Abstract][Full Text] [Related]
10. Six-second spirometry for detection of airway obstruction: a population-based study in Austria. Lamprecht B; Schirnhofer L; Tiefenbacher F; Kaiser B; Buist SA; Studnicka M; Enright P Am J Respir Crit Care Med; 2007 Sep; 176(5):460-4. PubMed ID: 17556719 [TBL] [Abstract][Full Text] [Related]
11. Correlation of airway hyper-responsiveness with obstructive spirometric indices and FEV(1) > 90% of predicted. Kotti GH; Bell DG; Matthews T; Lucero PF; Morris MJ Respir Care; 2012 Apr; 57(4):565-71. PubMed ID: 22004588 [TBL] [Abstract][Full Text] [Related]
12. Impact of bronchodilator use on the prevalence of COPD in population-based samples. Pérez-Padilla R; Hallal PC; Vázquez-García JC; Muiño A; Máquez M; López MV; de Oca MM; Tálamo C; Valdivia G; Pertuzé J; Jardim J; Menezes AM; COPD; 2007 Jun; 4(2):113-20. PubMed ID: 17530504 [TBL] [Abstract][Full Text] [Related]
13. FEV1 response to bronchodilation in an adult urban population. Kainu A; Lindqvist A; Sarna S; Lundbäck B; Sovijärvi A Chest; 2008 Aug; 134(2):387-393. PubMed ID: 18403671 [TBL] [Abstract][Full Text] [Related]
14. Bronchodilator and corticosteroid reversibility in ambulatory patients with airways obstruction. Dirksen A; Christensen H; Evald T; Jensen BV; Jensen JI; Keittelmann S; Vestbo J; Kok-Jensen A Dan Med Bull; 1991 Dec; 38(6):486-9. PubMed ID: 1839377 [TBL] [Abstract][Full Text] [Related]
15. [Restrictive pattern in spirometry: does FEV(1)/FVC need to be increased?]. Wesołowski S; Boros P Pneumonol Alergol Pol; 2011; 79(6):382-7. PubMed ID: 22028116 [TBL] [Abstract][Full Text] [Related]
16. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Schermer T; Heijdra Y; Zadel S; van den Bemt L; Boonman-de Winter L; Dekhuijzen R; Smeele I Respir Med; 2007 Jun; 101(6):1355-62. PubMed ID: 17098407 [TBL] [Abstract][Full Text] [Related]
17. Determining the time to maximal bronchodilator response in asthmatic children. Stavreska V; Verheggen M; Oostryck J; Stick SM; Hall GL J Asthma; 2009 Feb; 46(1):25-9. PubMed ID: 19191133 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of high-dose salmeterol in cystic fibrosis. Hordvik NL; Sammut PH; Judy CG; Colombo JL Pediatr Pulmonol; 2002 Oct; 34(4):287-96. PubMed ID: 12205570 [TBL] [Abstract][Full Text] [Related]
19. Baseline and post-bronchodilator interrupter resistance and spirometry in asthmatic children. Beydon N; Mahut B; Maingot L; Guillo H; La Rocca MC; Medjahdi N; Koskas M; Boulé M; Delclaux C Pediatr Pulmonol; 2012 Oct; 47(10):987-93. PubMed ID: 22328540 [TBL] [Abstract][Full Text] [Related]
20. Using post-bronchodilator FEV₁ is better than pre-bronchodilator FEV₁ in evaluation of COPD severity. Chen CZ; Ou CY; Wang WL; Lee CH; Lin CC; Chang HY; Hsiue TR COPD; 2012 Jun; 9(3):276-80. PubMed ID: 22360379 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]